Sclerosing cholangitis

Liver Disease in Children, Third Edition

Volumn , Issue , 2007, Pages 459-477

  Erickson, Nissa I ^a,b   Balistreri, William F ^c,d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Children's Hospital   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84927955103     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511547409.021     Document Type: Chapter

References (200)

1. Balistreri WF, Bove KE. Primary sclerosing cholangitis and similar hepatobiliary lesions. In: Balistreri WF, Vanderhoof JA, eds. Pediatric gastroenterology and nutrition. New York: Chapman & Hall, 1990:196–236.
2. Rodriguez HJ, Bass NM. Primary sclerosing cholangitis. Semin Gastrointest Dis 2003;14:189–98.
3. Mac Faul GR, Chapman RW. Sclerosing cholangitis. Curr Opin Gastroenterol 2004;20:275–80.
4. Ahmad J, Slivka A. Hepatobiliary disease in inflammatory bowel disease. Gastroenterol Clin North Am 2002;31:329–45.
5. Roberts EA. Primary sclerosing cholangitis in children. J Gastroenterol Hepatol 1999;14:588–93.
6. Gossard AA, Angulo P, Lindor KD. Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis. Am J Gastroenterol 2005;100:1330–3.
7. Mieli-Vergani G, Vergani D. Sclerosing cholangitis in the paediatric patient. Best Pract Res Clin Gastroenterol 2001;15:681–90.
8. Wilschanski M, Chait P, Wade JA, et al. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology 1995;22:1415–22.
9. Sisto A, Feldman P, Garel L, et al. Primary sclerosing cholangitis in children: study of five cases and review of the literature. Pediatrics 1987;80:918–23.
10. Feldstein AE, Perrault J, El-Youssif M, et al. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology 2003;38:210–17.
11. el-Shabrawi M, Wilkinson ML, Portmann B, et al. Primary sclerosing cholangitis in childhood. Gastroenterology 1987;92: 1226–35.
12. Debray D, Pariente D, Urvoas E, et al. Sclerosing cholangitis in children. J Pediatr 1994;124:49–56.
13. Batres LA, Russo P, Mathews M, et al. Primary sclerosing cholangitis in children: a histologic follow-up study. Pediatr Dev Pathol 2005;8:568–76.
14. Saarinen S, Olerup O, Broome U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol 2000;95:3195–9.
15. Jaffe R. Liver involvement in the histiocytic disorders of childhood. Pediatr Dev Pathol 2004;7:214–25.
16. Amedee-Manesme O, Bernard O, Brunelle F, et al. Sclerosing cholangitis with neonatal onset. J Pediatr 1987;111:225–9.
17. Baker AJ, Portmann B, Westaby D, et al. Neonatal sclerosing cholangitis in twosiblings: a categoryofprogressive intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 1993;17:317–22.
18. Bar Meir M, Hadas-Halperin I, Fisher D, et al. Neonatal sclerosing cholangitis associated with autoimmune phenomena. J Pediatr Gastroenterol Nutr 2000;30:332–4.
19. Ewart-Toland A, Enns GM, Cox VA, et al. Severe congenital anomalies requiring transplantation in children with Kabuki syndrome. Am J Med Genet 1998;80:362–7.
20. Nobili V, Marcellini M, Devito R, et al. Hepatic fibrosis in Kabuki syndrome. Am J Med Genet A 2004;124:209–12.
21. Baala L, Hadj-Rabia S, Hamel-Teillac D, et al. Homozygosity mapping of a locus for a novel syndromic ichthyosis to chromosome 3q27-q28. J Invest Dermatol 2002;119:70–6.
22. Hadj-Rabia S, Baala L, Vabres P, et al. Claudin-1 genemutations in neonatal sclerosing cholangitis associated with ichthyosis: a tight junction disease. Gastroenterology 2004;127:1386–90.
23. Beuers U, Rust C. Overlap syndromes. Semin Liver Dis 2005;25: 311–20.
24. Floreani A, Rizzotto ER, Ferrara F, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005;100:1516–22.
25. Hong-Curtis J, Yeh MM, Jain D, Lee JH. Rapid progression of autoimmune hepatitis in the background of primary sclerosing cholangitis. J Clin Gastroenterol 2004;38:906–9.
26. Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/ sclerosing cholangitis overlap syndromein childhood: a 16–year prospective study. Hepatology 2001;33:544–53.
27. Vergani D, Mieli-Vergani G. Autoimmune hepatitis and sclerosing cholangitis. Autoimmunity 2004;37:329–32.
28. Sekhon JS, Chung RT, Epstein M, Kaplan MM. Steroidresponsive (autoimmune?) sclerosing cholangitis. Dig Dis Sci 2005;50:1839–43.
29. Schrumpf E, Boberg KM. Epidemiology of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2001;15:553–62.
30. Bambha K, Kim WR, Talwalkar J, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003;125:1364–9.
31. Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 2002;51:562–6.
32. Talwalkar JA, Lindor KD. Primary sclerosing cholangitis. Inflamm Bowel Dis 2005;11:62–72.
33. Mendes FD, Lindor KD. Primary sclerosing cholangitis. Clin Liver Dis 2004;8:195–211.
34. Mac Faul GR, Chapman RW. Sclerosing cholangitis. Curr Opin Gastroenterol 2005;21:348–353.
35. Wiesner RH, Grambsch PM, Dickson ER, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989;10:430–6.
36. Farrant JM, Hayllar KM, Wilkinson ML, et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991;100:1710–17.
37. Okolicsanyi L, Fabris L, Viaggi S, et al. Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables: an Italianmulticentre study. The Italian PSC Study Group. Eur J Gastroenterol Hepatol 1996;8:685–91.
38. Broome U, Olsson R, Loof L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996;38:610–15.
39. Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991;11:31–9.
40. Loftus EVJr, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005;54:91–6.
41. Portincasa P, Vacca M, Moschetta A, et al. Primary sclerosing cholangitis: updates in diagnosis and therapy. World J Gastroenterol 2005;11:7–16.
42. Olsson R, Danielsson A, Jarnerot G, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991;100:1319–23.
43. Faubion WA Jr, Loftus EV, Sandborn WJ, et al. Pediatric “PSC–IBD”: a descriptive report of associated inflammatory bowel disease among pediatric patients with PSC. J Pediatr Gastroenterol Nutr 2001;33:296–300.
44. Aadland E, Schrumpf E, Fausa O, et al. Primary sclerosing cholangitis: a long-termfollow-up study. Scand J Gastroenterol 1987;22:655–64.
45. Broome U, Glaumann H, Lindstom E, et al. Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). J Hepatol 2002;36:586–9.
46. Hyams J, Markowitz J, Treem W, et al. Characterization of hepatic abnormalities in childrenwith inflammatory bowel disease. Inflamm Bowel Dis 1995;1:27–33.
47. Juillerat P, Mottet C, Froehlich F, et al. Extraintestinal manifestations of Crohn’s disease. Digestion 2005;71:31–6.
48. Raj V, Lichtenstein DR. Hepatobiliary manifestations of inflammatory bowel disease. Gastroenterol Clin North Am 1999;28: 491–513.
49. Kugathasan S, Judd RH, Hoffmann RG, et al. Epidemiologic and clinical characteristics of childrenwith newly diagnosed inflammatory bowel disease in Wisconsin: a statewide populationbased study. J Pediatr 2003;143:525–31.
50. Craig DA, Mac Carty RL, Wiesner RH, et al. Primary sclerosing cholangitis: value of cholangiography in determining the prognosis. AJR Am J Roentgenol 1991;157:959–64.
51. Mac Carty RL, La Russo NF, Wiesner RH, Ludwig J. Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology 1983;149:39–44.
52. Olsson RG, Asztely MS. Prognostic value of cholangiography in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 1995;7:251–4.
53. La Russo NF, Wiesner RH, Ludwig J, Mac Carty RL. Current concepts. Primary sclerosing cholangitis. N Engl J Med 1984;310: 899–903.
54. Angulo P, Pearce DH, Johnson CD, et al. Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis. J Hepatol 2000;33:520–7.
55. Fulcher AS, Turner MA, Franklin KJ, et al. Primary sclerosing cholangitis: evaluation with MR cholangiography—a case–control study. Radiology 2000;215:71–80.
56. Textor HJ, Flacke S, Pauleit D, et al. Three-dimensionalmagnetic resonance cholangiopancreatography with respiratory triggering in the diagnosis of primary sclerosing cholangitis: comparison with endoscopic retrograde cholangiography. Endoscopy 2002;34:984–90.
57. Ferrara C, Valeri G, Salvolini L, Giovagnoni A. Magnetic resonance cholangiopancreatography in primary sclerosing cholangitis in children. Pediatr Radiol 2002;32:413–17.
58. Lee WS, Saw CB, Sarji SA. Autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome in a child: diagnostic usefulness of magnetic resonance cholangiopancreatography. J Paediatr Child Health 2005;41:225–7.
59. Norton KI, Lee JS, Kogan D, et al. Therole ofmagnetic resonance cholangiography in the management of children and young adults after liver transplantation. Pediatr Transplant 2001;5: 410–18.
60. Brandsaeter B, Schrumpf E, Bentdal O, et al. Recurrent primary sclerosing cholangitis after liver transplantation: a magnetic resonance cholangiography study with analyses of predictive factors. Liver Transpl 2005;11:1361–9.
61. Macchi V, Floreani A, Marchesi P, et al. Imaging of primary sclerosing cholangitis: preliminary results by two new non-invasive techniques. Dig Liver Dis 2004;36:614–21.
62. Terjung B, Spengler U. Role of auto-antibodies for the diagnosis of chronic cholestatic liver diseases. Clin Rev Allergy Immunol 2005;28:115–33.
63. Angulo P, Peter JB, Gershwin ME, et al. Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol 2000;32:182–7.
64. Scheuer PJ. Ludwig Symposium on biliary disorders—part II. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis. Mayo Clin Proc 1998;73: 179–83.
65. Desmet VJ. Histopathology of chronic cholestasis and adult ductopenic syndrome. Clin Liver Dis 1998;2:249–64, viii.
66. Ludwig J. Surgical pathology of the syndrome of primary sclerosing cholangitis. Am J Surg Pathol 1989;13(Suppl 1):43–9.
67. Olsson R, Hagerstrand I, Broome U, et al. Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis. J Clin Pathol 1995;48:933–5.
68. Ludwig J. Small-duct primary sclerosing cholangitis. Semin Liver Dis 1991;11:11–17.
69. Angulo P, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis: a long-termfollow-up study. Hepatology 2002;35:1494–500.
70. Bjornsson E, Boberg KM, Cullen S, et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut 2002;51:731–5.
71. Boberg KM, Lundin KE, Schrumpf E. Etiology and pathogenesis in primary sclerosing cholangitis. Scand J Gastroenterol Suppl 1994;204:47–58.
72. Worthington J, Cullen S, Chapman R. Immunopathogenesis of primary sclerosing cholangitis. Clin Rev Allergy Immunol 2005;28:93–103.
73. Wu CT, Davis PA, Luketic VA, Gershwin ME. A review of the physiological and immunological functions of biliary epithelial cells: targets for primary biliary cirrhosis, primary sclerosing cholangitis and drug-induced ductopenias. Clin Dev Immunol 2004;11:205–13.
74. Broome U, Glaumann H, Hultcrantz R, Forsum U. Distribution of HLA-DR, HLA-DP, HLA-DQ antigens in liver tissue from patients with primary sclerosing cholangitis. Scand J Gastroenterol 1990;25:54–8.
75. Xu B, Broome U, Ericzon BG, Sumitran-Holgersson S. High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6. Gut 2002;51: 120–7.
76. Cruickshank SM, Southgate J, Wyatt JI, et al. Expression of CD44 on bile ducts in primary sclerosing cholangitis and primary biliary cirrhosis. J Clin Pathol 1999;52:730–4.
77. Quigley EM, La Russo NF, Ludwig J, et al. Familial occurrence of primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1983;85:1160–5.
78. Van Steenbergen W, De Goede E, Emonds MP, et al. Primary sclerosing cholangitis in two brothers: report of a family with special emphasis on molecular HLAand MICAgenotyping. Eur J Gastroenterol Hepatol 2005;17:767–71.
79. Silber GH, Finegold MJ, Wagner ML, Klish WJ. Sclerosing cholangitis and ulcerative colitis in a mother and her son. J Pediatr Gastroenterol Nutr 1987;6:147–52.
80. Spurkland A, Saarinen S, Boberg KM, et al. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens 1999;53:459–69.
81. Donaldson PT, Norris S. Evaluation of the role of MHC class II alleles, haplotypesandselectedaminoacid sequences inprimary sclerosing cholangitis. Autoimmunity 2002;35:555–64.
82. Norris S, Kondeatis E, Collins R, et al. Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: the role of MICA polymorphism. Gastroenterology 2001;120: 1475–82.
83. Wiencke K, Spurkland A, Schrumpf E, Boberg KM. Primary sclerosing cholangitis is associated to an extended B8-DR3 haplotype including particular MICAand MICBalleles. Hepatology 2001;34:625–30.
84. Sheth S, Shea JC, Bishop MD, et al. Increased prevalence of CFTRmutations and variants and decreased chloride secretion in primary sclerosing cholangitis. Hum Genet 2003;113:286–92.
85. Girodon E, Sternberg D, Chazouilleres O, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene defects in patients with primary sclerosing cholangitis. J Hepatol 2002; 37:192–7.
86. Gallegos-Orozco JF, E Yurk C, Wang N, et al. Lack of association of common cystic fibrosis transmembrane conductance regulator gene mutations with primary sclerosing cholangitis. Am J Gastroenterol 2005;100:874–8.
87. Mc Gill JM, Williams DM, Hunt CM. Survey of cystic fibrosis transmembrane conductance regulator genotypes in primary sclerosing cholangitis. Dig Dis Sci 1996;41:540–2.
88. Grant AJ, Lalor PF, Salmi M, et al. Homing ofmucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002;359:150–7.
89. Grant AJ, Lalor PF, Hubscher SG, et al. MAd CAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAd CAM-1 in chronic inflammatory liver disease). Hepatology 2001;33:1065–72.
90. Eksteen B, Grant AJ, Miles A, et al. Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med 2004;200:1511–17.
91. Eksteen B, Miles AE, Grant AJ, Adams DH. Lymphocyte homing in the pathogenesis of extra-intestinal manifestations of inflammatory bowel disease. Clin Med 2004;4:173–80.
92. Vierling JM. Hepatobiliary complications of ulcerative colitis and Crohn’s disease. In: Zakim D, Boyer TD, eds. Hepatology: a textbook of liver disease. 2nd ed. Philadelphia: WB Saunders, 1990:1126–58.
93. Lichtman SN, Sartor RB, Keku J, Schwab JH. Hepatic inflammation in ratswith experimental small intestinal bacterial overgrowth. Gastroenterology 1990;98:414–23.
94. Olsson R, Bjornsson E, Backman L, et al. Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers. J Hepatol 1998;28:426–32.
95. Goddard EA, Mouton SC, Westwood AT, et al. Cryptosporidiosis of the gastrointestinal tract associatedwith sclerosing cholangitis in the absence of documented immunodeficiency: cryptosporidium parvum and sclerosing cholangitis in an immunocompetent child. J Pediatr Gastroenterol Nutr 2000;31:317–20.
96. Nilsson HO, Taneera J, Castedal M, et al. Identification of Helicobacter pylori and other Helicobacter species by PCR, hybridization, and partial DNAsequencing in human liver samples from patients with primary sclerosing cholangitis or primary biliary cirrhosis. J Clin Microbiol 2000;38:1072–6.
97. Wadstrom T, Ljungh A, Willen R. Primary biliary cirrhosis and primary sclerosing cholangitis are of infectious origin! Gut 2001;49:454.
98. Ponsioen CY, Defoer J, Ten Kate FJ, et al. A survey of infectious agents as risk factors for primary sclerosing cholangitis: are Chlamydia species involved? Eur J Gastroenterol Hepatol 2002; 14:641–8.
99. Minuk GY, Rascanin N, Paul RW, et al. Reovirus type 3 infection in patientswith primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 1987;5:8–13.
100. Minuk GY, Paul RW, Lee PW. The prevalence of antibodies to reovirus type 3 in adultswith idiopathic cholestatic liver disease. J Med Virol 1985;16:55–60.
101. Lichtman SN, Keku J, Clark RL, et al. Biliary tract disease in rats with experimental small bowel bacterial overgrowth. Hepatology 1991;13:766–72.
102. Lichtman SN, Keku J, Schwab JH, Sartor RB. Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline. Gastroenterology 1991;100:513–19.
103. Koga H, Sakisaka S, Yoshitake M, et al. Abnormal accumulation in lipopolysaccharide in biliary epithelial cells of rats with selffilling blind loop. Int J Mol Med 2002;9:621–6.
104. Numata Y, Tazuma S, Nishioka T, et al. Immune response in mouse experimental cholangitis associated with colitis induced by dextran sulfate sodium. J Gastroenterol Hepatol 2004;19: 910–15.
105. Numata Y, Tazuma S, Ueno Y, et al. Therapeutic effect of repeated natural killer T cell stimulation in mouse cholangitis complicated by colitis. Dig Dis Sci 2005;50:1844–51.
106. Fickert P, Fuchsbichler A, Wagner M, et al. Regurgitation of bile acids fromleaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2004;127:261–74.
107. Popov Y, Patsenker E, Fickert P, et al. Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol 2005;43: 1045–54.
108. Ng VL, Balistreri WF. Treatment options for chronic cholestasis in infancy and childhood. Curr Treat Options Gastroenterol 2005;8:419–30.
109. Angulo P. Use of ursodeoxycholic acid in patients with liver disease. Curr Gastroenterol Rep 2002;4:37–44.
110. Balistreri WF. Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. J Pediatr Gastroenterol Nutr 1997;24:573–89.
111. Marschall HU, Wagner M, Zollner G, et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005;129:476–85.
112. Trauner M, Graziadei IW. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther 1999;13:979–96.
113. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997;336:691–5.
114. Chen W, Gluud C. Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev 2003:CD003626.
115. Mitchell SA, Bansi DS, Hunt N, et al. Apreliminary trial of highdose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121:900–7.
116. Harnois DM, Angulo P, Jorgensen RA, et al. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001;96:1558–62.
117. Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005;129:1464–72.
118. Chapman RW. The management of primary sclerosing cholangitis. Curr Gastroenterol Rep 2003;5:9–17.
119. Rust C, Beuers U. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. Clin Rev Allergy Immunol 2005;28:135–45.
120. Chen W, Gluud C. Glucocorticosteroids for primary sclerosing cholangitis. Cochrane Database Syst Rev 2004:CD004036.
121. Cox KL, Cox KM. Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1998;27:580–3.
122. Schramm C, Schirmacher P, Helmreich-Becker I, et al. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series. Ann Intern Med 1999;131:943–6.
123. Stiehl A, Rost D. Endoscopic treatment of dominant stenoses in patients with primary sclerosing cholangitis. Clin Rev Allergy Immunol 2005;28:159–65.
124. Stiehl A, Rudolph G, Kloters-Plachky P, et al. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002;36:151–6.
125. Ponsioen CY, Lam K, van Milligen de Wit AW, et al. Four years experience with short termstenting in primary sclerosing cholangitis. Am J Gastroenterol 1999;94:2403–7.
126. Van Milligen de Wit AW, Rauws EA, van Bracht J, et al. Lack of complications following short-term stent therapy for extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc 1997;46:344–7.
127. Angulo P, Larson DR, Therneau TM, et al. Time course of histological progression in primary sclerosing cholangitis. Am J Gastroenterol 1999;94:3310–13.
128. Bjoro K, Schrumpf E. Liver transplantation for primary sclerosing cholangitis. J Hepatol 2004;40:570–7.
129. Annual Report from the Studies of Pediatric Liver Transplantation (SPLIT). (Includes data from the registry as of June 1, 2005.) (Accessed at http:www. splitregistry. com.)
130. Wiesner RH. Liver transplantation for primary sclerosing cholangitis: timing, outcome, impact of inflammatory bowel disease and recurrence of disease. Best Pract Res Clin Gastroenterol 2001;15:667–80.
131. Solano E, Khakhar A, Bloch M, et al. Liver transplantation for primary sclerosing cholangitis. Transplant Proc 2003;35:2431–4.
132. Kugelmas M, Spiegelman P, Osgood MJ, et al. Differentimmunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2003;9:727–32.
133. Abu-Elmagd KM, Balan V. Recurrent primary sclerosing cholangitis: from an academic illusion to a clinical reality. Liver Transpl 2005;11:1326–8.
134. Graziadei IW. Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2002;8:575–81.
135. Vera A, Moledina S, Gunson B, et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 2002;360:1943–4.
136. Boberg KM, Rocca G, Egeland T, et al. Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis. Hepatology 2002;35:652–7.
137. Boberg KM, Spurkland A, Rocca G, et al. The HLA-DR3, DQ2 heterozygous genotype is associated with an accelerated progression of primary sclerosing cholangitis. Scand J Gastroenterol 2001;36:886–90.
138. Boberg KM, Schrumpf E. Diagnosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep 2004;6:52–9.
139. Burak K, Angulo P, Pasha TM, et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004;99:523–6.
140. Chalasani N, Baluyut A, Ismail A, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 2000;31:7–11.
141. Ross AMT, Anupindi SA, Balis UJ. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 11–2003. A 14-year-old boy with ulcerative colitis, primary sclerosing cholangitis, and partial duodenal obstruction. N Engl J Med 2003;348:1464–76.
142. Belghiti J. Transplantation for liver tumors. Semin Oncol 2005; 32:29–32.
143. Brandsaeter B, Isoniemi H, Broome U, et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequencesof hepatobiliary malignancy. JHepatol 2004;40:815–22.
144. Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 1997;41:522–5.
145. Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002;56:48–54.
146. Vera A, Gunson BK, Ussatoff V, et al. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 2003;75:1983–8.
147. Okazaki K, Uchida K, Matsushita M, Takaoka M. Autoimmune pancreatitis. Intern Med 2005;44:1215–23.
148. Ichimura T, Kondo S, Ambo Y, et al. Primary sclerosing cholangitis associated with autoimmune pancreatitis. Hepatogastroenterology 2002;49:1221–4.
149. Kaukinen K, Halme L, Collin P, et al. Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. Gastroenterology 2002;122:881–8.
150. Wurm P, Dixon AD, Rathbone BJ. Ulcerative colitis, primary sclerosing cholangitis and coeliac disease: two cases and review of the literature. Eur J Gastroenterol Hepatol 2003;15:815–17.
151. Al-Osaimi AM, Berg CL. Association of primary sclerosing cholangitis and celiac disease: a case report and review of the literature. Dig Dis Sci 2004;49:438–43.
152. Abraham S, Begum S, Isenberg D. Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis 2004;63:123–9.
153. Kadokawa Y, Omagari K, Matsuo I, et al. Primary sclerosing cholangitis associated with lupus nephritis: a rare association. Dig Dis Sci 2003;48:911–14.
154. Toda K, Yasuda I, Nishigaki Y, et al. Inflammatory pseudotumor of the liver with primary sclerosing cholangitis. J Gastroenterol 2000;35:304–9.
155. Toosi MN, Heathcote J. Pancreatic pseudotumorwith sclerosing pancreato-cholangitis: is this a systemic disease?. Am J Gastroenterol 2004;99:377–82.
156. Bartholomew LG, Cain JC, Woolner LB,. Sclerosing cholangitis: its possible association with Riedel’s struma and fibrous retroperitonitis. Report of two cases. NEngl JMed 1963;269:8–12.
157. Alpert LI, Jindrak K. Idiopathic retroperitoneal fibrosis and sclerosing cholangitis associated with a reticulum cell sarcoma. Report of a case. Gastroenterology 1972;62:111–17.
158. Kamisawa T, Nakajima H, Egawa N, et al. Ig G4-related sclerosing disease incorporating sclerosing pancreatitis, cholangitis, sialadenitis and retroperitoneal fibrosiswith lymphadenopathy. Pancreatology 2005;6:132–7.
159. Rodrigues F, Davies EG, Harrison P, et al. Liver disease in children with primary immunodeficiencies. J Pediatr 2004;145: 333–9.
160. Cappell MS. Hepatobiliary manifestations of the acquired immune deficiency syndrome. Am J Gastroenterol 1991;86:1–15.
161. Hashmey R, Smith NH, Cron S, et al. Cryptosporidiosis in Houston, Texas. A report of 95 cases. Medicine (Baltimore) 1997;76:118–39.
162. Rodriguez C, Carrion F, Marinovic MA, et al. [X-linked hyper- IGM syndrome associated to sclerosing cholangitis and gallbladder neoplasm: clinical case]. Rev Med Chil 2003;131: 303–8. [Article in Spanish]
163. Lin SC, Shyur SD, Ma YC, et al. Recurrent acalculous cholecystitis and sclerosing cholangitis in a patient with X-linked hyper-immunoglobulin M syndrome. J Formos Med Assoc 2005;104:421–6.
164. Dimicoli S, Bensoussan D, Latger-Cannard V, et al. Complete recovery from Cryptosporidium parvum infection with gastroenteritis and sclerosing cholangitis after successful bonemarrow transplantation in two brothers with X-linked hyper-Ig M syndrome. Bone Marrow Transplant 2003;32:733–7.
165. Kahn K, Sharp H, Hunter D, et al. Primary sclerosing cholangitis in Wiskott–Aldrich syndrome. J Pediatr Gastroenterol Nutr 2001;32:95–9.
166. Kahana DD, Cass O, Jessurun J, et al. Sclerosing cholangitis associated with trichosporon infection and natural killer cell deficiency in an 8-year-old girl. J Pediatr Gastroenterol Nutr 2003;37:620–3.
167. Misbah SA, Spickett GP, Zeman A, et al. Progressive multifocal leucoencephalopathy, sclerosing cholangitis, bronchiectasis and disseminated warts in a patient with primary combined immune deficiency. J Clin Pathol 1992;45:624–7.
168. Davis JJ, Heyman MB, Ferrell L, et al. Sclerosing cholangitis associated with chronic cryptosporidiosis in a child with a congenital immunodeficiency disorder. Am J Gastroenterol 1987;82:1196–202.
169. Klein C, Lisowska-Grospierre B, Le Deist F, et al. Major histocompatibility complex class II deficiency: clinical manifestations, immunologic features, and outcome. J Pediatr 1993;123: 921–8.
170. Bucuvalas JC, Bove KE, Kaufman RA, et al. Cholangitis associated with Cryptococcus neoformans. Gastroenterology 1985; 88:1055–9.
171. Urushihara N, Ariki N, Oyama T, et al. Secondary sclerosing cholangitis and portal hypertension after O157 enterocolitis: extremely rare complications of hemolytic uremic syndrome. J Pediatr Surg 2001;36:1838–40.
172. Engler S, Elsing C, Flechtenmacher C, et al. Progressive sclerosing cholangitis after septic shock: a new variant of vanishing bile duct disorders. Gut 2003;52:688–93.
173. Gupta A, Roebuck DJ, Michalski AJ. Biliary involvement in Hodgkin’s disease. Pediatr Radiol 2002;32:202–4.
174. Man KM, Drejet A, Keeffe EB, et al. Primary sclerosing cholangitis and Hodgkin’s disease. Hepatology 1993;18:1127–31.
175. Wegerle W, Garbrecht M, Nerl C, Schmitt W. [Angioimmunoblastic lymphadenopathy with dysproteinemia and sclerosing cholangitis]. Dtsch Med Wochenschr 1994;119: 332–7. [Article in German]
176. Benninger J, Grobholz R, Oeztuerk Y, et al. Sclerosing cholangitis following severe trauma: description of a remarkable disease entitywith emphasisonpossible pathophysiologicmechanisms. World J Gastroenterol 2005;11:4199–205.
177. Castellano G, Moreno-Sanchez D, Gutierrez J, et al. Caustic sclerosing cholangitis. Report of four cases and a cumulative review of the literature. Hepatogastroenterology 1994;41:458–70.
178. Ciftci AO, Karnak I, Senocak ME, et al. Surgical injury of the biliary tract in children. Eur J Pediatr Surg 2000;10:100–5.
179. Strandvik B, Hjelte L, Gabrielsson N, Glaumann H. Sclerosing cholangitis in cystic fibrosis. Scand J Gastroenterol Suppl 1988; 143:121–4.
180. Durieu I, Pellet O, Simonot L, et al. Sclerosing cholangitis in adults with cystic fibrosis: a magnetic resonance cholangiographic prospective study. J Hepatol 1999;30:1052–6.
181. Farkkila M, Karvonen AL, Nurmi H, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 2004;40:1379–86.
182. Polter DE, Gruhl V, Eigenbrodt EH, Combes B. Beneficial effect of cholestyramine in sclerosing cholangitis. Gastroenterology 1980;79:326–33.
183. Duchini A, Younossi ZM, Saven A, et al. An open-label pilot trial of cladibrine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis. J Clin Gastroenterol 2000;31:292–6.
184. Olsson R, Broome U, Danielsson A, et al. Colchicine treatment of primary sclerosing cholangitis. Gastroenterology 1995;108: 1199–203.
185. Lindor KD, Wiesner RH, Colwell LJ, et al. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am J Gastroenterol 1991;86:57–61.
186. Angulo P, Batts KP, Jorgensen RA, et al. Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000;95:2333–7.
187. Kyokane K, Ichihara T, Horisawa M, et al. Successful treatment of primary sclerosing cholangitis with cyclosporine and corticosteroid. Hepatogastroenterology 1994;41:449–52.
188. Knox TA, Kaplan MM. Treatment of primary sclerosing cholangitis with oral methotrexate. Am J Gastroenterol 1991;86:546–52.
189. Knox TA, Kaplan MM. A double-blind controlled trial of oralpulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994;106:494–9.
190. Talwalkar JA, Angulo P, Keach JC, et al. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2005;100:308–12.
191. Klingenberg S, Chen W. D-penicillamine for primary sclerosing cholangitis. Cochrane Database Syst Rev 2006:CD004182.
192. Bharucha AE, Jorgensen R, Lichtman SN, et al. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000;95:2338–42.
193. Angulo P, Mac Carty RL, Sylvestre PB, et al. Pirfenidone in the treatmentof primary sclerosing cholangitis. Dig Dis Sci 2002;47: 157–61.
194. Van Thiel DH, Carroll P, Abu-Elmagd K, et al. Tacrolimus (FK 506), a treatmentfor primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995;90:455–9.
195. Gilger MA, Gann ME, Opekun AR, Gleason WA Jr. Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children. J Pediatr Gastroenterol Nutr 2000;31: 136–41.
196. Allison MC, Burroughs AK, Noone P, Summerfield JA. Biliary lavage with corticosteroids in primary sclerosing cholangitis. A clinical, cholangiographic and bacteriological study. J Hepatol 1986;3:118–22.
197. Kaya M, Petersen BT, Angulo P, et al. Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol 2001;96:1059–66.
198. Baluyut AR, Sherman S, Lehman GA, et al. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 2001;53:308–12.
199. Hirai I, Ishiyama S, Fuse A, et al. Primary sclerosing cholangitis successfully treated by resection of the confluence of the hepatic duct. J Hepatobiliary Pancreat Surg 2001;8:169–73.
200. Loehe F, Schauer RJ. Surgical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. Clin Rev Allergy Immunol 2005;28:167–74.